Lunit Inc
KOSDAQ:328130
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (19.1), the stock would be worth ₩-7 855.46 (121% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -92.8 | ₩38 200 |
0%
|
| Industry Average | 19.1 | ₩-7 855.46 |
-121%
|
| Country Average | 14.8 | ₩-6 097.39 |
-116%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
L
|
Lunit Inc
KOSDAQ:328130
|
1.4T KRW | -92.8 | -16.4 | |
| JP |
|
Medical Data Vision Co Ltd
TSE:3902
|
37.9T JPY | 86.2 | 227.5 | |
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD | 28.3 | 53.1 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
26B USD | 13.9 | 28.6 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
14.4B AUD | 116.7 | 60.5 | |
| JP |
|
M3 Inc
TSE:2413
|
1T JPY | 16.8 | 20.8 | |
| SE |
|
Sectra AB
STO:SECT B
|
50.7B SEK | 73.9 | 94.4 | |
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4.8B USD | 21.5 | 42.1 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.5B USD | 12.4 | 19 | |
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
19.1B CNY | 77.7 | -61.9 | |
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR | 66.3 | -328 |
Market Distribution
| Min | 0 |
| 30th Percentile | 8.7 |
| Median | 14.8 |
| 70th Percentile | 28.4 |
| Max | 4 181.4 |
Other Multiples
Lunit Inc
Glance View
Lunit Inc., founded in South Korea, stands as a pioneering force in the application of artificial intelligence within the realm of medical technology. As a company at the intersection of healthcare and cutting-edge AI, Lunit crafts advanced solutions that enhance the diagnostic processes in radiology and oncology. The company's name, derived from "learning unit," underscores its mission to employ deep learning as a core component in transforming medical diagnostics. At the heart of Lunit’s operations are their flagship products, Lunit INSIGHT and Lunit SCOPE, which are designed to empower physicians by providing highly accurate diagnostic readings and treatment predictions. With this technology, Lunit aims to reduce diagnostic errors and improve the efficiency of medical imaging analysis, ultimately enhancing patient treatment outcomes. Lunit generates revenue through strategic partnerships and sales of their AI software solutions to hospitals and healthcare providers globally. The company's business model involves not only licensing its AI technologies but also integrating them with existing medical imaging equipment, thus enhancing the value derived from traditional diagnostic tools. By collaborating with prominent medical device manufacturers and healthcare institutions, Lunit ensures both the scalability and adaptability of its products in diverse clinical settings. Additionally, they actively engage in research collaborations and pilot programs to further their technological advancements and expand their market presence. Through these endeavors, Lunit is steadily carving out a crucial role in the healthcare sector by offering AI-driven solutions that promise to revolutionize patient care.